| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 78.6% (206 of 262) of all reports.WarningH315 (20.6%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 262 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Regulatorische Informationen | Chemical: Hexanoic acid, 6-amino-Hexanoic acid, 6-amino- is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Hexanoic acid, 6-amino- are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Status: Active Update: 24-10-2022 https://echa.europa.eu/registration-dossier/-/registered-dossier/22890Hexanoic acid, 6-amino-: Does not have an individual approval but may be used under an appropriate group standard |
|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Hexanoic acid, 6-amino-: Environment tier I assessment |
|---|
| Gefahrenübersicht | Possible side effects in long-term therapy greater than 2 weeks include seizures, myopathy, renal failure, and kidney failure[HSDB] May cause irritationEffects in high-dose animal studies include convulsions or effect on seizure threshold and changes in the renal tubules[MSDSonline] Not teratogenic in rabbits[REPROTOX] |
|---|
| Special Reports | REVIEW: A PROFILE OF THE PHARMACOLOGY, THERAPEUTIC INDICATIONS, THE PREPARATIONS AND STRENGTHS AVAILABLE, THE DOSAGE, CONTRAINDICATIONS, TOXICITY, INTERACTIONS, PHARMACOKINETICS AND OTHER PHYSICAL PROPERTIES OF EPSILON-AMINOCAPROIC ACID.[PROFILE ON EPSILON AMINOCAPROIC ACIDAUST J PHARM 62(JUN) 403 (1981)] |
|---|
| Hazard Classes and Categories | Skin Irrit. 2 (20.6%) |
|---|
| Wechselwirkungen | PLASMINOGEN ACTIVATORS SUCH AS STREPTOKINASE & UROKINASE ARE USED TO TREAT THROMBOEMBOLIC DISORDERS. ...AMINOCAPROIC ACID COUNTERACTS THE THROMBOLYTIC EFFECT OF THESE DRUGS... |
|---|
| Unerwünschte Wirkungen | Neurotoxin - Other CNS neurotoxinAlthough aminocaproic acid is generally well tolerated in patients, reported adverse effects of the drug include malaise, myalgias, renal impairment, seizures, hypotension, bradycardia, thrombosis, edemas, and injection site reactions. Less frequently, aminocaproic acid may also lead to gastrointestinal symptoms, such as nausea and diarrhea. In addition, there have been reports of nasal congestion and conjunctival suffusion with the usage of aminocaproic acid. |
|---|
| Toxizitätsübersicht | Aminocaproic acid is associated with a low acute toxicity risk. Research on teratogenic in vitro studies has revealed no fetal abnormalities when administering aminocaproic acid dosages up to 5000 mcg/kg/d. Retinal changes have been reported in dogs after receiving aminocaproic acid orally over 1 year at doses approximately 7 times higher than the maximum recommended dose for in vivo use. A significant concern regarding aminocaproic acid treatment is whether this drug can increase patients' risk of thrombosis and intravascular coagulation. Although there are isolated reports of arterial or venous thrombosis, it is noteworthy that the underlying thrombotic comorbidity is present in each reported case. |
|---|
| Human Toxicity Excerpts | CARDIAC & HEPATIC NECROSES WERE FOUND @ POSTMORTEM EXAMINATION IN ONE PT WHO HAD RECEIVED THERAPEUTIC DOSES OF THE DRUG.AMINOCAPROIC ACID MAY CAUSE ITCHING, ERYTHEMA, SKIN RASH, DIURESIS, HEARTBURN, NAUSEA, & DIARRHEA. ...HAS ANTIADRENERGIC EFFECT SIMILAR TO GUANETHIDINE, SO THAT NASAL STUFFINESS, CONJUNCTIVAL SUFFUSION, & HYPOTENSION MAY OCCUR. ...MAY ENHANCE THROMBOTIC PROCESSES BY SUPPRESSION OF REACTIVE FIBRINOLYSIS...AMICAR HAS BEEN USED IN SUBARACHNOID HEMORRHAGE TO PROMOTE CLOTTING, BUT CEREBRAL THROMBOSIS HAS BEEN REPORTED IN VARIOUS VASCULAR COMPARTMENTS FOLLOWING ITS USE. TWO PATIENTS ARE DESCRIBED WHO HAD CEREBRAL ANGIOGRAPHY AFTER AMICAR THERAPY WHICH DEMONSTRATED THROMBOSIS UNRELATED TO VASCULAR SPASM OR TO TECHNICAL COMPLICATIONS OF ANGIOGRAPHY. |
|---|
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Aminocaproic acidvNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
|---|
| Non-Human Toxicity Excerpts | /AMINOCAPROIC ACID/...IS TERATOGENIC IN ANIMALS...SUBENDOCARDIAL HEMORRHAGES & MYOCARDIAL DEPRESSION HAVE BEEN ASSOCIATED WITH ADMIN OF AMINOCAPROIC ACID IN SEVERAL ANIMAL SPECIES. DRUG MAY TRANSIENTLY ALTER PROTEIN METABOLISM BY INHIBITING UTILIZATION OF LYSINE....WHEN GIVEN IV TO CATS HAS SYMPATHOMIMETIC EFFECTS, INCL DILATED PUPILS & EXOPHTHALMOS ATTRIBUTABLE PARTLY TO RELEASE OF CATECHOLAMINES. ...CHRONICALLY BY MOUTH IT OCCASIONALLY CAUSES NASAL CONGESTION & CONJUNCTIVAL HYPEREMIA. |
|---|
